InvestorsHub Logo
Post# of 253059
Next 10
Followers 838
Posts 120392
Boards Moderated 18
Alias Born 09/05/2002

Re: DewDiligence post# 221566

Friday, 11/30/2018 11:19:25 AM

Friday, November 30, 2018 11:19:25 AM

Post# of 253059
DVAX –6% on phase-2 asthma flop:

https://www.sec.gov/Archives/edgar/data/1029142/000156459018030292/dvax-8k_20181129.htm

Dynavax Technologies Corporation…has been informed by its collaborator, AstraZeneca, that initial high-level results from a Phase 2a study indicate AZD1419 treatment was not associated with a statistically significant improvement in the time to loss of asthma control and therefore did not meet the primary endpoint of the study.

No press release.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.